UB Paderborn / Katalog / Suche / in CDI

PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A65-A66

2022

Link zum Volltext

Verfügbarkeit prüfen

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

The New England journal of medicine, 2022-07, Vol.387 (4), p.321-331

2022

Link zum Volltext

Verfügbarkeit prüfen

PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A103-A103

2022

Link zum Volltext

Verfügbarkeit prüfen

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A16-A16

2022

Link zum Volltext

Verfügbarkeit prüfen

Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C‐HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF‐36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitat

Arthritis care & research (2010), 2011-11, Vol.63 (S11), p.S118-S157

2011

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome measures for cutaneous lupus erythematosus

Lupus, 2010-08, Vol.19 (9), p.1137-1143

2010

Link zum Volltext

Verfügbarkeit prüfen

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

Annals of the Rheumatic Diseases, 2010-07, Vol.69 (7), p.1269-1274

2010

Link zum Volltext

Verfügbarkeit prüfen

Response to: 'Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups'' by Irfan et al

Annals of the rheumatic diseases, 2023-02, Vol.82 (2), p.e41

2023

Link zum Volltext

Verfügbarkeit prüfen

Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise

Journal of the American Academy of Dermatology, 2017-08, Vol.77 (2), p.261-267

2017

Link zum Volltext

Verfügbarkeit prüfen

Importance of recognition and improved treatment for antimelanoma differentiation‐associated protein 5‐associated dermatomyositis

British journal of dermatology (1951), 2017-11, Vol.177 (5), p.1168-1169

2017

Link zum Volltext

Verfügbarkeit prüfen

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

Journal of the American Academy of Dermatology, 2008-06, Vol.58 (6), p.1043-1046

2008

Link zum Volltext

Verfügbarkeit prüfen

Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.853-854

2017

Link zum Volltext

Verfügbarkeit prüfen

A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach

Journal of multidisciplinary healthcare, 2019-01, Vol.12, p.419-428

2019

Link zum Volltext

Verfügbarkeit prüfen

Defining anti-synthetase syndrome: a systematic literature review

Clinical and experimental rheumatology, 2022-02, Vol.40 (2), p.309

2022

Link zum Volltext

Verfügbarkeit prüfen

Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study

Rheumatology (Oxford, England), 2023-04, Vol.62 (4), p.1711-1715

2023

Link zum Volltext

Verfügbarkeit prüfen

International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus

Journal of dermatology, 2024-07, Vol.51 (7), p.881-884

2024

Link zum Volltext

Verfügbarkeit prüfen

The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus

Journal of investigative dermatology, 2005-11, Vol.125 (5), p.889-894

2005

Link zum Volltext

Verfügbarkeit prüfen

Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review

Clinical and experimental rheumatology, 2024-02, Vol.42 (2), p.403

2024

Link zum Volltext

Verfügbarkeit prüfen

Moving forward together: collaborative landscapes of research in idiopathic inflammatory myopathies and calcinosis

Rheumatology (Oxford, England), 2024-05, Vol.63 (5), p.1189-1191

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

British journal of dermatology (1951), 2017-01, Vol.176 (1), p.231-233

2017

Link zum Volltext

Verfügbarkeit prüfen

Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: A review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual

International journal of dermatology, 2004-02, Vol.43 (2), p.87-94

2004

Link zum Volltext

Verfügbarkeit prüfen

Thalidomide in cutaneous lupus erythematosus

American journal of clinical dermatology, 2003, Vol.4 (6), p.379-387

2003

Link zum Volltext

Verfügbarkeit prüfen

Clinical manifestations of cutaneous lupus erythematosus

Autoimmunity reviews, 2005-06, Vol.4 (5), p.296-302

Werth, Victoria P.

2005

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists

British journal of dermatology (1951), 2017-10, Vol.177 (4), p.1086-1092

2017

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

PO.4.75 The anti-BDCA2 antibody biib059 improves joint and skin manifestations in patients with SLE and both active arthritis and rash

Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus

PO.6.135 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and phase II study design in patients with SLE and/or CLE (WILLOW)

S11.2 Efficacy and safety of deucravacitinib, a selective TYK2 inhibitor, in patients with active systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study

Clinical outcome measures for cutaneous lupus erythematosus

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies

Response to: 'Correspondence on 'EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups'' by Irfan et al

Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise

Importance of recognition and improved treatment for antimelanoma differentiation‐associated protein 5‐associated dermatomyositis

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

Dermatological evaluation in patients with skin of colour: the effect of erythema on outcome measures in atopic dermatitis

A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach

Defining anti-synthetase syndrome: a systematic literature review

Anti-transcription intermediary factor 1-gamma IgG2 isotype is associated with cancer in adult dermatomyositis: an ENMC multinational study

International exchange on the clinical practice and research of rheumatic skin diseases: A report of the 5th International Conference of Cutaneous Lupus Erythematosus

The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus

Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review

Moving forward together: collaborative landscapes of research in idiopathic inflammatory myopathies and calcinosis

Clinical signs associated with an increased risk of interstitial lung disease: a retrospective study of 101 patients with dermatomyositis

Lupus erythematosus induced by medications, ultraviolet radiation, and other exogenous agents: A review, with special focus on the development of subacute cutaneous lupus erythematosus in a genetically predisposed individual

Thalidomide in cutaneous lupus erythematosus

Clinical manifestations of cutaneous lupus erythematosus

Collaborative research in myositis-related disorders: MIHRA, a global shared community model

Evaluation of the reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index and the Cutaneous Assessment Tool–Binary Method in juvenile dermatomyositis among paediatric dermatologists, rheumatologists and neurologists

Suchergebnisse filtern